MarketCap
Facebook
X
TelegramQuarterly report 2026-Q2
added 06-01-2026
Agilent Technologies Total Assets 2011-2026 | A
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Agilent Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.7 B | 11.8 B | 10.8 B | 10.5 B | 10.7 B | 9.63 B | 9.45 B | 8.54 B | 8.43 B | 7.8 B | 7.48 B | 10.8 B | 10.7 B | 10.5 B | 9.06 B | 9.7 B | 7.61 B | 7.01 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 B | 7.01 B | 9.63 B |
Quarterly Total Assets Agilent Technologies
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.1 B | 12.8 B | 12.8 B | 12.7 B | 12.2 B | 11.9 B | 11.9 B | 11.8 B | - | 10.9 B | - | 10.7 B | 10.8 B | 10.8 B | 10.3 B | 10.5 B | - | 10.5 B | 9.67 B | 10.7 B | 10.5 B | 10.7 B | 9.5 B | 9.63 B | 9.63 B | 9.46 B | 8.95 B | 9.45 B | 9.45 B | 9.45 B | 8.7 B | 8.56 B | 8.56 B | 8.56 B | 7.87 B | 8.43 B | 8.43 B | 8.43 B | 7.3 B | 7.79 B | 7.79 B | 7.79 B | 7.52 B | 7.48 B | 7.48 B | 7.48 B | 10.6 B | 10.8 B | 10.8 B | 10.8 B | 10.7 B | 10.7 B | 10.7 B | 10.7 B | 9.1 B | 10.5 B | 10.5 B | 10.5 B | 8.04 B | 9.06 B | 9.06 B | 9.06 B | 9.1 B | 7.77 B | 7.57 B | 6.57 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 B | 6.57 B | 9.71 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 206.18 | 0.82 % | $ 22.9 B | USA |
 |
Celcuity
CELC
|
467 M | $ 89.53 | -3.31 % | $ 4.19 B | USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 4.63 | 2.88 % | $ 6.16 M | USA |
 |
Castle Biosciences
CSTL
|
579 M | $ 21.44 | 1.68 % | $ 621 M | USA |
 |
Fulgent Genetics
FLGT
|
1.21 B | $ 19.12 | 3.35 % | $ 588 M | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
28.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.3 B | $ 152.76 | 0.62 % | $ 12 B |  Irlanda |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
2.01 B | $ 131.71 | 1.22 % | $ 16.5 B | USA |
 |
Illumina
ILMN
|
6.64 B | $ 165.78 | 3.59 % | $ 25.7 B | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 23.21 | 2.02 % | $ 1.24 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.74 | 3.57 % | $ 7.7 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.19 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 102.44 | 2.46 % | $ 6.91 B | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 193.18 | 1.68 % | $ 9.57 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.42 | 3.28 % | $ 426 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 475.39 | 1.84 % | $ 13.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 162.13 | -0.07 % | $ 24 B |  Schweiz |
 |
NeoGenomics
NEO
|
1.36 B | $ 11.74 | 2.62 % | $ 1.5 B | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.66 | 2.53 % | $ 432 M | USA |
 |
National Research Corporation
NRC
|
135 M | $ 20.98 | 6.23 % | $ 470 M | USA |
 |
Natera
NTRA
|
2.4 B | $ 222.41 | -0.19 % | $ 30.4 B | USA |
 |
Personalis
PSNL
|
334 M | $ 10.26 | 5.23 % | $ 916 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 25.84 | -2.49 % | $ 24.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
126 M | $ 7.65 | 2.9 % | $ 319 M | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
564 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.03 | -1.02 % | $ 4.66 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 274.38 | 1.17 % | $ 22.8 B | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 492.63 | -0.34 % | $ 186 B | USA |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.68 | 2.39 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
642 M | $ 70.12 | 0.09 % | $ 4.19 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.32 | 0.38 % | $ 2.02 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |